Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage therapeutics company it exposes no public developer API surface.
Forty Seven * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immuno-Oncology, and Oncology.
Forty Seven *’s developer surface includes engineering blog and 4 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/forty-seven/"><img src="https://apis.io/badge/forty-seven/card.svg" alt="Forty Seven * on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey) Ask about this →
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented) Ask about this →
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes Ask about this →
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
Each check links to what satisfies it. Publish the artifact, or tell us where it already lives, and the score moves on the next scoring run.
Not sure how this applies to your stack? Ask about any one item. Kin Lane reads every question, looks at your profile and your situation, and replies with what a fix would take — scoped to that one area, priced up front, yours whether you ship it or not. Ask a question →
aid: forty-seven
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
- url: http://fortyseveninc.com
status: 307
note: declared website redirects to https://www.gilead.com/ — a different registrable domain (fortyseveninc.com -> gilead.com),
possible rename or acquisition (probed 2026-09-03, roadmap#169)
generated: '2026-11-13'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven.png
name: Forty Seven *
description: Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion
research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal
antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic
syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired
by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage
therapeutics company it exposes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-10-06'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- url: https://www.gilead.com/stories
type: Blog
- type: CrunchBase
url: https://www.crunchbase.com/organization/forty-seven-inc
- type: ParentCompany
url: https://apis.io/providers/gilead-sciences/
name: Gilead Sciences
x-relationship: acquired
x-evidence: Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.
- type: DomainSecurity
url: security/forty-seven-domain-security.yml
- type: Website
url: http://fortyseveninc.com
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
x-parent: gilead-sciences
x-relationship: acquisition
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.